openPR Logo
Press release

Chikungunya Fever Market Segmentation 2018 with Recent Trend by 2023

11-27-2018 10:56 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Market Research Future

Chikungunya Fever Market

Chikungunya Fever Market

Chikungunya Fever Market - Highlights

Chikungunya fever is a mosquito borne disease. The caU.S.Ative agent is a RNA virus that belongs to the alphavirus genus of the family Togaviridae. The transmission of the disease occurs from human to human by the bites of infected female mosquitoes. Most commonly, the mosquitoes involved are Aedes aegypti and Aedes albopictus. The symptoms of the disease includes muscle pain, headache, nausea, fatigue and rash.

There is no specific antiviral drug treatment for Chikungunya. Treatment is directed primarily at relieving the symptoms. This involves use of anti-pyretics, optimal analgesics in allopathy. Moreover, ayurveda and homeopathy can be employed in the treatment procedures.

According to the World Health Organization, the disease mostly occurs in Africa, Asia and the Indian subcontinent. However a major outbreak in 2015 affected several countries of the region of the Americas. This is expected to boost the market growth across the globe during the forecasted period.

The global chikungunya fever market is expected to grow at a CAGR of 5.86% during the forecast period.

Request Sample Report @ https://www.marketresearchfuture.com/sample_request/5094

Chikungunya Fever Market - Key Players

The key players for the chikungunya market are Quest Diagnostics Incorporated. (U.S.A), Alere. (U.S.A), Genome Diagnostics Pvt. Ltd. (India), altona Diagnostics (Europe), Bio-Rad Laboratories, Inc. (U.S.A), Sanat Products Ltd. (India), Taj Pharmaceuticals Limited. (India), and Etubics Corporation (U.S.A).

Chikungunya Fever Market - Segmentation               

The chikungunya fever market is segmented on the basis of diagnosis, treatment, and end users.

On the basis of diagnosis, the market is segmented into ELISA based assays, serological tests, virological tests, and others. ELISA based assays is futhur segmented into IgM based ELISA and IgG ELISA. On the basis of treatment, the market is segmented into allopathy, homeopathy, ayurveda, and others.

The allopathy segmented is sub segmented into anti-pyretics, optimal analgesics, and others. The homeopathy segment is sub segmented into pyroginum, rhus-tox, cedron, and others. The ayurveda segment is sub segmented into amrutharista, mahasudarshana churna, dhanvantaram gutika and others. On the basis of end users, the market is segmented into hospitals and clinics, academic institutes, research laboratories, and others.

Chikungunya Fever Market - Regional Analysis

The Americas dominate the global chikungunya fever market owing to a large patient population, strong government support for research & development, and high healthcare spending. Moreover, presence of the global market leaders within the regions facilitates the market growth within the region during the forecasted period.

Europe has the second leading market in global chikungunya fever market which is followed by Asia Pacific. Asia Pacific is the fastest growing market for chikungunya fever. On 22 September 2017, according to the European Centre for Disease Prevention and Control there were about 102 autochthonous chikungunya cases in Italy. Moreover, similar cases were reported in France. Such factors in the presence of a well-developed healthcare infrastructure along with high per capita healthcare expenditures made Europe to generate high revenues for the global chikungunya fever market.  Asia Pacific chikungunya fever market is majorly driven by Indian and China owing to a huge patient pool, and continuously developing healthcare sector have fuelled the growth of the market.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures at https://www.marketresearchfuture.com/reports/malocclusion-market-5094

The Middle East and Africa contribute the least in the growth of global chikungunya fever market. The Middle East dominates the market for The Middle East and Africa. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East market. Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition. However the growth of the Africa market is high due to the presence of opportunities for the development of the market.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chikungunya Fever Market Segmentation 2018 with Recent Trend by 2023 here

News-ID: 1401567 • Views:

More Releases from Market Research Future

Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR by 2032
Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR …
Market Overview: The Intravenous (IV) Solution Market is estimated to be valued at USD 13.9 billion in 2023 and is projected to reach USD 26.60 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.70% from 2024 to 2031. The market growth is attributed to the rising prevalence of chronic diseases, growing hospitalization rates, and increasing surgical procedures that require IV fluid administration. Intravenous solutions are critical
Laboratory Equipment Market Projected to Reach USD 102.11 Billion with 7.66% CAGR by 2032
Laboratory Equipment Market Projected to Reach USD 102.11 Billion with 7.66% CAG …
Market Overview: The Laboratory Equipment Market is estimated to be valued at USD 49.6 billion in 2024 and is projected to reach USD 78.2 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031. The market growth is primarily driven by the rising demand for advanced research tools in pharmaceuticals, biotechnology, clinical diagnostics, and academic institutes. Increasing investment in R&D activities, coupled with technological
Medical Second Opinion Market Set to Grow to USD 21.36 Billion at a 14.30% CAGR by 2034
Medical Second Opinion Market Set to Grow to USD 21.36 Billion at a 14.30% CAGR …
Market Overview: The Medical Second Opinion Market is estimated to grow significantly from 2024 to 2031, driven by the rising need for accurate diagnosis, treatment validation, and better patient care. A second opinion helps patients make more informed healthcare decisions, particularly in cases of complex surgeries, rare diseases, or chronic illnesses. With increasing awareness among patients about medical errors and the importance of exploring alternative treatments, the demand for medical second
Penicillin Drug Market Forecasted to Surpass USD 14.36 Billion at a 3.64% CAGR by 2034
Penicillin Drug Market Forecasted to Surpass USD 14.36 Billion at a 3.64% CAGR b …
Market Overview: The Penicillin Drug Market is estimated to be valued significantly in 2024 and is projected to grow steadily, reaching a substantial valuation by 2031. This growth is driven by the continued reliance on penicillin as a frontline antibiotic and its wide therapeutic applications in bacterial infection management. Penicillin remains one of the most widely prescribed antibiotics globally, with demand sustained by rising bacterial infection prevalence, increasing healthcare expenditure, and

All 5 Releases


More Releases for Chikungunya

Chikungunya market is expected to reach USD 1.4 billion by 2034
Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), transmitted primarily by Aedes aegypti and Aedes albopictus. The infection is characterized by sudden high fever, severe joint pain, rash, headache, and fatigue. While rarely fatal, chikungunya often leads to chronic arthritis-like symptoms lasting months to years, creating a significant burden on healthcare systems. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71953 Global spread is accelerating due to
Chikungunya Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportu …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. What Is the Projected Growth of the Chikungunya Market? In recent times, there has been robust growth in the chikungunya market size. It is projected to expand from $0.59 billion in 2024 to $0.65 billion in 2025, with a compound annual growth rate (CAGR) of 9.8%. Factors that have contributed to this
Chikungunya Pipeline Insight 2025: 10+ Advancing Therapies and Key Companies in …
The therapeutic landscape for Chikungunya, a viral disease transmitted by mosquitoes that causes severe joint pain, fever, and rash, is rapidly evolving, fueled by advancements in antiviral research and vaccine development. Leading biopharmaceutical companies such as Valneva, Moderna Therapeutics, Themis Bioscience, FIT Biotech, Bharat Biotech, and Emergex Vaccines are at the forefront of developing innovative therapies, targeting various stages of the virus lifecycle, immune modulation, and pain management to alleviate
Chikungunya Fever Global Clinical Trials Review, H2, 2018: Researchmoz.us
Researchmoz added Most up-to-date research on "Chikungunya Fever Global Clinical Trials Review, H2, 2018" to its huge collection of research reports. An insight on the important factors and trends influencing the market. Latest clinical trial report, Chikungunya Fever Global Clinical Trials Review, H2, 2018" provides an overview of Chikungunya Fever clinical trials scenario. This report provides top line data relating to the clinical trials on Chikungunya Fever. Report includes an overview
Chikungunya Fever Market Worldwide Segmentation with Top Key Merchant – Avail …
Chikungunya Fever Market - Highlights Chikungunya fever is a mosquito borne disease. The caU.S.Ative agent is a RNA virus that belongs to the alphavirus genus of the family Togaviridae. The transmission of the disease occurs from human to human by the bites of infected female mosquitoes. Most commonly, the mosquitoes involved are Aedes aegypti and Aedes albopictus. The symptoms of the disease includes muscle pain, headache, nausea, fatigue and rash. There is
Chikungunya Fever (Infectious Disease) Pipeline Forecast Report, H1, 2017 - Phar …
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chikungunya Fever Market- Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chikungunya Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press